{"id":"bezafibrate","rwe":[{"pmid":"41869905","year":"2026","title":"Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.","finding":"","journal":"Alimentary pharmacology & therapeutics","studyType":"Clinical Study"},{"pmid":"41818730","year":"2026","title":"Long-term safety and efficacy of oral bezafibrate use in dogs with hypertriglyceridemia.","finding":"","journal":"Journal of veterinary internal medicine","studyType":"Clinical Study"},{"pmid":"41757235","year":"2026","title":"Comparative effectiveness of pemafibrate versus bezafibrate on hepatic and vascular endothelial function in patients with coronary artery disease and metabolic dysfunction-associated steatotic liver disease.","finding":"","journal":"Frontiers in endocrinology","studyType":"Clinical Study"},{"pmid":"41672548","year":"2026","title":"Bezafibrate prolongs hypothermia induced by an A(1) adenosine receptor agonist in CBA/N mice.","finding":"","journal":"The Journal of veterinary medical science","studyType":"Clinical Study"},{"pmid":"41662914","year":"2026","title":"Pan-PPAR agonist bezafibrate alleviates psoriasis by suppressing LCN2-dependent ferroptosis.","finding":"","journal":"Free radical biology & medicine","studyType":"Clinical Study"}],"tags":[{"label":"bezafibrate","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Fatty acid-binding protein, intestinal","category":"target"},{"label":"FABP2","category":"gene"},{"label":"PPARD","category":"gene"},{"label":"PPARA","category":"gene"},{"label":"C10AB02","category":"atc"},{"label":"Active","category":"status"},{"label":"Hypercholesterolemia","category":"indication"},{"label":"Hyperlipidemia","category":"indication"},{"label":"Antimetabolites","category":"pharmacology"},{"label":"Hypolipidemic Agents","category":"pharmacology"},{"label":"Lipid Regulating Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":59.83,"date":"","count":19,"signal":"Diverticular perforation","source":"DrugCentral FAERS","actionTaken":"Reported 19 times (LLR=60)"},{"llr":55.402,"date":"","count":22,"signal":"Hypertriglyceridaemia","source":"DrugCentral FAERS","actionTaken":"Reported 22 times (LLR=55)"},{"llr":51.002,"date":"","count":36,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 36 times (LLR=51)"},{"llr":50.188,"date":"","count":90,"signal":"Acute kidney injury","source":"DrugCentral FAERS","actionTaken":"Reported 90 times (LLR=50)"},{"llr":48.181,"date":"","count":12,"signal":"Vascular stent stenosis","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=48)"},{"llr":45.655,"date":"","count":29,"signal":"Pancreatitis acute","source":"DrugCentral FAERS","actionTaken":"Reported 29 times (LLR=46)"},{"llr":45.224,"date":"","count":13,"signal":"Coronary artery thrombosis","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=45)"},{"llr":43.026,"date":"","count":11,"signal":"Arterial stenosis","source":"DrugCentral FAERS","actionTaken":"Reported 11 times (LLR=43)"},{"llr":42.132,"date":"","count":12,"signal":"Helicobacter gastritis","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=42)"},{"llr":41.956,"date":"","count":12,"signal":"Carotid arteriosclerosis","source":"DrugCentral FAERS","actionTaken":"Reported 12 times (LLR=42)"},{"llr":41.601,"date":"","count":9,"signal":"Cor pulmonale acute","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=42)"},{"llr":39.151,"date":"","count":35,"signal":"Rhabdomyolysis","source":"DrugCentral FAERS","actionTaken":"Reported 35 times (LLR=39)"},{"llr":35.761,"date":"","count":28,"signal":"Blood creatine phosphokinase increased","source":"DrugCentral FAERS","actionTaken":"Reported 28 times (LLR=36)"},{"llr":35.205,"date":"","count":42,"signal":"Renal impairment","source":"DrugCentral FAERS","actionTaken":"Reported 42 times (LLR=35)"},{"llr":34.241,"date":"","count":9,"signal":"Cardiorenal syndrome","source":"DrugCentral FAERS","actionTaken":"Reported 9 times (LLR=34)"}],"commonSideEffects":[],"contraindications":["End stage renal disease"]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:37:35.414229","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BEZAFIBRATE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:52:15.517752+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Bezafibrate","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-19T23:52:24.670092+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:52:22.944428+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BEZAFIBRATE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:52:23.610855+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3739769/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:52:24.320672+00:00"}},"allNames":"befizal","offLabel":[],"synonyms":["bezafibrate","befizal","benzofibrate","difaterol","bezatol","bezalip"],"timeline":[{"date":"1978-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"brandName":"Befizal","ecosystem":[{"indication":"Hypercholesterolemia","otherDrugs":[{"name":"alirocumab","slug":"alirocumab","company":"Sanofi Aventis"},{"name":"atorvastatin","slug":"atorvastatin","company":"Pfizer"},{"name":"cerivastatin","slug":"cerivastatin","company":"Bayer Pharms"},{"name":"cholestyramine","slug":"cholestyramine","company":"Bristol Myers"}],"globalPrevalence":390000000},{"indication":"Hyperlipidemia","otherDrugs":[{"name":"cholestyramine","slug":"cholestyramine","company":"Bristol Myers"},{"name":"choline fenofibrate","slug":"choline-fenofibrate","company":"Abbvie"},{"name":"clofibrate","slug":"clofibrate","company":""},{"name":"colestipol","slug":"colestipol","company":"Pharmacia And Upjohn"}],"globalPrevalence":390000000}],"mechanism":{"target":"Fatty acid-binding protein, intestinal","targets":[{"gene":"FABP2","source":"DrugCentral","target":"Fatty acid-binding protein, intestinal","protein":"Fatty acid-binding protein, intestinal"},{"gene":"PPARD","source":"DrugCentral","target":"Peroxisome proliferator-activated receptor delta","protein":"Peroxisome proliferator-activated receptor delta"},{"gene":"PPARA","source":"DrugCentral","target":"Peroxisome proliferator-activated receptor alpha","protein":"Peroxisome proliferator-activated receptor alpha"},{"gene":"PPARG","source":"DrugCentral","target":"Peroxisome proliferator-activated receptor gamma","protein":"Peroxisome proliferator-activated receptor gamma"},{"gene":"HMGCR","source":"DrugCentral","target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","protein":"3-hydroxy-3-methylglutaryl-coenzyme A reductase"},{"gene":"LPL","source":"DrugCentral","target":"Lipoprotein lipase","protein":"Lipoprotein lipase"}],"modality":"Small Molecule","drugClass":"bezafibrate","explanation":"","oneSentence":"","technicalDetail":"Bezafibrate acts as a PPAR-alpha agonist, which leads to increased expression of genes involved in fatty acid oxidation, resulting in enhanced breakdown of fatty acids in the liver and increased excretion of lipids into the bile."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Bezafibrate","title":"Bezafibrate","extract":"Bezafibrate is a fibrate drug used as a lipid-lowering agent to treat hyperlipidaemia. It helps to lower LDL cholesterol and triglyceride in the blood, and increase HDL.","wiki_history":"==History==\nBezafibrate was first introduced by Boehringer Mannheim in 1977."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/362","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BEZAFIBRATE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BEZAFIBRATE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Bezafibrate","fields":["history","overview"],"source":"Wikipedia"}],"_enrichedAt":"2026-03-30T09:03:08.307488","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:52:25.970402+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"clofibrate","drugSlug":"clofibrate","fdaApproval":"1967-02-08","genericCount":5,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"gemfibrozil","drugSlug":"gemfibrozil","fdaApproval":"1981-12-21","genericCount":18,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"fenofibrate","drugSlug":"fenofibrate","fdaApproval":"1993-12-31","patentExpiry":"May 31, 2033","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"choline fenofibrate","drugSlug":"choline-fenofibrate","fdaApproval":"2008-12-15","genericCount":12,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"bezafibrate","indications":{"approved":[{"name":"Hypercholesterolemia","source":"DrugCentral","snomedId":13644009,"regulator":"FDA","usPrevalence":86000000,"globalPrevalence":390000000,"prevalenceMethod":"curated","prevalenceSource":"WHO Global Health Estimates, 2023"},{"name":"Hyperlipidemia","source":"DrugCentral","snomedId":55822004,"regulator":"FDA","usPrevalence":null,"globalPrevalence":390000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2023"}],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(1850)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"clofibrate","brandName":"clofibrate","genericName":"clofibrate","approvalYear":"1967","relationship":"same-class"},{"drugId":"gemfibrozil","brandName":"gemfibrozil","genericName":"gemfibrozil","approvalYear":"1981","relationship":"same-class"},{"drugId":"fenofibrate","brandName":"fenofibrate","genericName":"fenofibrate","approvalYear":"1993","relationship":"same-class"},{"drugId":"choline-fenofibrate","brandName":"choline fenofibrate","genericName":"choline fenofibrate","approvalYear":"2008","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07319442","phase":"","title":"CEDUR - German IBD Registry","status":"RECRUITING","sponsor":"ImmunoRegister gUG","startDate":"2018-05-03","conditions":["Ulcerative Colitis (UC)","Indeterminate Colitis","Crohn Disease (CD)"],"enrollment":10000,"completionDate":"2036-05"},{"nctId":"NCT04594694","phase":"PHASE2","title":"Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC","status":"TERMINATED","sponsor":"Intercept Pharmaceuticals","startDate":"2019-10-02","conditions":["Primary Biliary Cholangitis"],"enrollment":75,"completionDate":"2025-10-14"},{"nctId":"NCT06488911","phase":"PHASE3","title":"To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate","status":"TERMINATED","sponsor":"Intercept Pharmaceuticals","startDate":"2024-07-01","conditions":["Primary Biliary Cholangitis"],"enrollment":63,"completionDate":"2025-10-21"},{"nctId":"NCT02481245","phase":"PHASE2","title":"BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2018-01-11","conditions":["Bipolar Disorder","Depressive Episode"],"enrollment":30,"completionDate":"2026-02-28"},{"nctId":"NCT05239468","phase":"PHASE2","title":"Study of OCA in Combination With BZF Evaluating Efficacy, Safety and Tolerability in Participants With PBC","status":"COMPLETED","sponsor":"Intercept Pharmaceuticals","startDate":"2022-03-21","conditions":["Primary Biliary Cholangitis"],"enrollment":72,"completionDate":"2025-09-01"},{"nctId":"NCT06443606","phase":"PHASE3","title":"Efficacy and Safety of Bezafibrate 400 mg and Bezafibrate 200 mg as Adjunctive Treatments in Patients With Primary Biliary Cholangitis and Non-optimal Biochemical Response to Ursodeoxycholic Acid Therapy","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03-27","conditions":["BPC","Non Optimal Response to UDCA"],"enrollment":108,"completionDate":"2029-06-01"},{"nctId":"NCT06858332","phase":"","title":"Lipoprotein(a) Levels in Patients With Atherosclerotic Cardiovascular Diseases in Russia","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-15","conditions":["Atherosclerotic Cardiovascular Disease"],"enrollment":2382,"completionDate":"2027-09-30"},{"nctId":"NCT04997811","phase":"PHASE2","title":"Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes","status":"UNKNOWN","sponsor":"Prof. Janet Dunn","startDate":"2021-12-21","conditions":["Myelodysplastic Syndromes (MDS)"],"enrollment":120,"completionDate":"2025-06-30"},{"nctId":"NCT04561466","phase":"PHASE2,PHASE3","title":"Trial of Befizal® 200 mg for the Treatment of Leber Hereditary Optic Neuropathy","status":"COMPLETED","sponsor":"Hôpital Necker-Enfants Malades","startDate":"2019-03-26","conditions":["Safety Issues","Efficacy, Self"],"enrollment":14,"completionDate":"2023-03-10"},{"nctId":"NCT01654731","phase":"PHASE3","title":"Phase 3 Study of Bezafibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cirrhosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-10-15","conditions":["PBC"],"enrollment":100,"completionDate":"2016-12-31"},{"nctId":"NCT02548832","phase":"PHASE3","title":"Bezafibrate Plus Berberine in Mixed Dyslipidemia","status":"COMPLETED","sponsor":"University of Guadalajara","startDate":"2013-04","conditions":["Mixed Dyslipidemia"],"enrollment":36,"completionDate":"2020-04-01"},{"nctId":"NCT04514965","phase":"","title":"Bezafibrate in Patients With Primary Biliary Cholangitis (PBC)","status":"RECRUITING","sponsor":"University of Aarhus","startDate":"2020-10-01","conditions":["Primary Biliary Cirrhosis"],"enrollment":100,"completionDate":"2026-09"},{"nctId":"NCT04309773","phase":"PHASE3","title":"Efficacy of 24 Month of Bezafibrate in Primary Sclerosing Cholangitis With Persistent Cholestasis Despite Ursodeoxycholic Acid Therapy","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-04-06","conditions":["Primary Sclerosing Cholangitis","Cholestasis"],"enrollment":104,"completionDate":"2025-03"},{"nctId":"NCT05213988","phase":"NA","title":"Effects on Glucose Homeostasis of Changes in Plasma Lipoproteins Induced by Nutritional and Pharmacologic Strategies","status":"UNKNOWN","sponsor":"Azienda Ospedaliero, Universitaria Pisana","startDate":"2018-07-30","conditions":["Glucose Metabolism Disorders"],"enrollment":50,"completionDate":"2025-01-01"},{"nctId":"NCT04751188","phase":"PHASE3","title":"A Study to Assess Efficacy and Safety of Bezafibrate in Patients With Primary Biliary Cholangitis","status":"UNKNOWN","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2020-10-02","conditions":["Primary Biliary Cirrhosis"],"enrollment":11,"completionDate":"2021-07"},{"nctId":"NCT02984982","phase":"PHASE4","title":"Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2016-11-15","conditions":["Hypercholesterolemia","Acute Coronary Syndrome"],"enrollment":206,"completionDate":"2018-07-27"},{"nctId":"NCT02584504","phase":"PHASE3","title":"Efficacy and Safety of Alirocumab in Patients With Hypercholesterolemia Not Adequately Controlled With Non-statin Lipid Modifying Therapy or the Lowest Strength of Statin","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11-30","conditions":["Hypercholesterolemia"],"enrollment":163,"completionDate":"2018-01-09"},{"nctId":"NCT03649269","phase":"NA","title":"PC-300 Tea Effect on Triglyceride Levels","status":"COMPLETED","sponsor":"Ciprés Grupo Médico CGM SC","startDate":"2014-01-01","conditions":["Hypertriglyceridemia"],"enrollment":34,"completionDate":"2014-12-31"},{"nctId":"NCT02937012","phase":"PHASE3","title":"Use of Bezafibrate in Patients With Primary Biliary Cirrhosis to Archive Complete Biochemical Response in Non-responders","status":"UNKNOWN","sponsor":"Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran","startDate":"2016-10","conditions":["Primary Biliary Cirrhosis"],"enrollment":34,"completionDate":"2019-12"},{"nctId":"NCT02398201","phase":"PHASE2","title":"A Study of Bezafibrate in Mitochondrial Myopathy","status":"COMPLETED","sponsor":"Newcastle-upon-Tyne Hospitals NHS Trust","startDate":"2015-09","conditions":["Mitochondrial Diseases"],"enrollment":6,"completionDate":"2017-03-23"},{"nctId":"NCT02701166","phase":"PHASE3","title":"The Effect of Bezafibrate on Cholestatic Itch","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2016-02","conditions":["Primary Biliary Cholangitis","Primary Sclerosing Cholangitis","Secondary Sclerosing Cholangitis"],"enrollment":84,"completionDate":"2018-04"},{"nctId":"NCT02291796","phase":"PHASE4","title":"Bezafibrate for Hyperfibrinogenemia in Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Instituto Mexicano del Seguro Social","startDate":"2011-01","conditions":["Acute Myocardial Infarction"],"enrollment":100,"completionDate":"2013-12"},{"nctId":"NCT01527318","phase":"PHASE4","title":"The Effect of Fibrate Therapy in Two Patients With Neutral Lipid Storage Disease With Myopathy (NLSDM)","status":"COMPLETED","sponsor":"Maastricht University Medical Center","startDate":"2011-08","conditions":["Neutral Lipid Storage Disease"],"enrollment":6,"completionDate":"2012-12"},{"nctId":"NCT00983788","phase":"PHASE2","title":"Effect of Bezafibrate on Muscle Metabolism in Patients With Fatty Acid Oxidation Defects","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2009-10","conditions":["Carnitine Palmitoyltransferase II Deficiency","Very Long Chain Acyl Coa Dehydrogenase Deficiency"],"enrollment":12,"completionDate":"2011-09"},{"nctId":"NCT01165060","phase":"NA","title":"The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)","status":"COMPLETED","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2010-07","conditions":["X-linked Adrenoleukodystrophy","Adrenomyeloneuropathy"],"enrollment":10,"completionDate":"2011-08"},{"nctId":"NCT00506298","phase":"PHASE2","title":"Study of CRx-401 on Glucose Levels in Subjects With Type II Diabetes","status":"COMPLETED","sponsor":"Zalicus","startDate":"2007-07","conditions":["Type 2 Diabetes"],"enrollment":150,"completionDate":"2009-05"},{"nctId":"NCT00336167","phase":"PHASE3","title":"Bezafibrate Trial in CPT2 Deficiency","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2006-06","conditions":["Carnitine Palmitoyl Transferase 2 Deficiency"],"enrollment":12,"completionDate":"2007-07"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000166742","NDDF":"003937","UNII":"Y9449Q51XH","CHEBI":"CHEBI:47612","INN_ID":"3968","RXNORM":"1525","UMLSCUI":"C0005330","chemblId":"CHEMBL3739769","ChEMBL_ID":"CHEMBL264374","KEGG_DRUG":"D01366","DRUGBANK_ID":"DB01393","PDB_CHEM_ID":"PEM","PUBCHEM_CID":"39042","SNOMEDCT_US":"319937007","IUPHAR_LIGAND_ID":"2668","MESH_DESCRIPTOR_UI":"D001629"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"99%"},"publicationCount":1852,"therapeuticAreas":["Metabolic"],"atcClassification":{"source":"DrugCentral","atcCode":"C10AB02","allCodes":["C10AB02"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 29","pmid":"41906662","title":"Review Article: Targeting Peroxisome Proliferator-Activated Receptors in Primary Biliary Cholangitis.","journal":"Alimentary pharmacology & therapeutics"},{"date":"2026 Mar 23","pmid":"41869905","title":"Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.","journal":"Alimentary pharmacology & therapeutics"},{"date":"2026 Mar 2","pmid":"41818730","title":"Long-term safety and efficacy of oral bezafibrate use in dogs with hypertriglyceridemia.","journal":"Journal of veterinary internal medicine"},{"date":"2026","pmid":"41757235","title":"Comparative effectiveness of pemafibrate versus bezafibrate on hepatic and vascular endothelial function in patients with coronary artery disease and metabolic dysfunction-associated steatotic liver disease.","journal":"Frontiers in endocrinology"},{"date":"2026 Feb 11","pmid":"41672548","title":"Bezafibrate prolongs hypothermia induced by an A(1) adenosine receptor agonist in CBA/N mice.","journal":"The Journal of veterinary medical science"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:52:25.970402+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}